Skip to content

To Compare the effect of glycopyrronium and indacaterol fixed dose combination once daily versus tiotropium and formoterol fixed-dose combination once daily in patients with moderate to severe chronic obstructive pulmonary disease

To Compare the effect of glycopyrronium and indacaterol fixed dose combination versus tiotropium and formoterol fixed-dose combination in patients with moderate to severe chronic obstructive pulmonary disease - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/104661
Enrollment
100
Registered
2026-02-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention1: Glycopyrronium and indacetrol fixed dose combination once daily in moderate to severe chronic obstructive pulmonary disease patients: Glycopyrronium 50 mcg and indacetrol 110 mcg fixe

Sponsors

Department of chest and Tb university of health sciences vallah amritsar punjab
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged more than 18 years non smaokers or ex smokers and had a diagnosis of chronic obstructive and pulmonary diseases with presence of respiratory symptoms postbronchodilator forced expiratory volume in one second divided by forced vital capacity ratio of less than 70 percentage and postbronchodilator forced expiratory volume more than equal to 30 percentage and less than 80 percentage of predicted

Exclusion criteria

Exclusion criteria: Pregnant and or lactating mothers. Patients with diagnosis of asthma. Known underlying cardiovascular abnormalities like arrhythmias, congestive heart failure, coronary heart disease. Patients with history of hospitalization for pneumonia within 3 months of enrolment. Patients with history of use of oral or parentral corticosteroid or depot corticosteroid use 6 weeks before the enrolment. Contraindications or hypersensitivity to any of the study drugs. Suspected presence of active TB and other communicable diseases. Patients with neurological , musculoskeletal and peripheral vascular diseases. Active hemoptysis is also contraindication

Design outcomes

Primary

MeasureTime frame
To help better access of superior inhaler combination among glycopyrronium and indacetrol fixed dose combination versus tiotropium and formetrol fixed dose combination in patients with moderate to severe chronic obstructive pulmonary diseaseTimepoint: Time points will be at baseline 6 weeks and then at 12 weeks

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Sunil Grover

Sri Guru Ram Das University of Health Sciences

drsunilgrover332@gmail.com9872307333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026